More than 130 suppliers
ISO certified
In-house tech support
we Connect you
Bio-Connect
ProductsBack/bpV(phen) [171202-16-7]
Chemical Structure
Chemical Structure
Chemical Structure

bpV(phen) [171202-16-7]

Research Use Only
AG-CR1-0042
AdipoGen Life Sciences
CAS Number171202-16-7
DownloadDatasheet
DownloadMSDS
Product group Chemicals
Estimated Purity>99% (51V-NMR)
Molecular Weight350.2 . 54.0
Price on request
Packing Size
Large volume orders?
Order with a bulk request
More than 130 suppliers
ISO certified
In-house tech support

Overview

  • Supplier
    AdipoGen Life Sciences
  • Product Name
    bpV(phen) [171202-16-7]
  • Delivery Days Customer
    10
  • CAS Number
    171202-16-7
  • Certification
    Research Use Only
  • Estimated Purity
    >99% (51V-NMR)
  • Hazard Information
    Non-hazardous
  • Molecular Formula
    K[VO(O2)2C12H8N2] . 3H2O
  • Molecular Weight
    350.2 . 54.0
  • Scientific Description
    Chemical. CAS: 171202-16-7. Formula: K[VO(O2)2C12H8N2] . 3H2O. MW: 350.2 . 54.0. Potent protein phosphotyrosine phosphatase inhibitor. Insulin receptor kinase (IRK) inducer. Insulin mimetic in vitro and in vivo. Apoptosis inducer. ERK inducer. Mitogen-activated protein kinase phosphatase-1 (MKP-1) inducer. Angiogenesis inhibitor. PTEN inhibitor. - Potent protein phosphotyrosine phosphatase inhibitor [1, 2, 5]. Insulin receptor kinase (IRK) inducer [2]. Insulin mimetic in vitro and in vivo [3, 4]. Apoptosis inducer [6]. ERK inducer [7]. Mitogen-activated protein kinase phosphatase-1 (MKP-1) inducer [7]. Angiogenesis inhibitor [8]. PTEN inhibitor [9].
  • SMILES
    C1[N]2=CC=CC3=C2C2=[N]1C=CC=C2C=C3
  • Storage Instruction
    2°C to 8°C,-20°C
  • UNSPSC
    12352200

References

  • Peroxovanadium compounds. A new class of potent phosphotyrosine phosphatase inhibitors which are insulin mimetics: B.I. Posner, et al.; J. Biol. Chem. 269, 4596 (1994)
  • Early signaling events triggered by peroxovanadium [bpV(phen)] are insulin receptor kinase (IRK)-dependent: specificity of inhibition of IRK-associated protein tyrosine phosphatase(s) by bpV(phen): C.J. Band, et al.; Mol. Endocrinol. 11, 1899 (1997)
  • Hypoglycemic effects of peroxovanadium compounds in Sprague-Dawley and diabetic BB rats: J.F. Yale, et al.; Diabetes 44, 1274 (1995)
  • In vivo insulin mimetic effects of pV compounds: role for tissue targeting in determining potency: A.P. Bevan, et al.; Am. J. Physiol. 268, E60 (1995)
  • A role for tyrosine phosphorylation in both activation and inhibition of the insulin receptor tyrosine kinase in vivo: P.G. Drake, et al.; Endocrinology 137, 4960 (1996)
  • BpV (phen) induces apoptosis of RINm5F cells by modulation of MAPKs and MKP-1: L. Rumora, et al.; BBRC 300, 877 (2003)
  • Positive regulation of ERK activation and MKP-1 expression by peroxovanadium complex bpV (phen): L. Rumora, et al.; Cell Biol. Toxicol. 20, 293 (2004)
  • Peroxovanadium compounds as inhibitors of angiogenesis: C. J. Doillon, et al.; Angiogenesis 3, 361 (1999)
  • Bisperoxovanadium compounds are potent PTEN inhibitors: A.C. Schmid, et al.; FEBS Lett. 566, 35 (2004)